Trials
3 active
3 in total · 3 in the EU
What this is
- How it works
- A short strand of RNA that switches off one gene, so the body makes less of one protein.-siran: small interfering RNA WHO name stem
- Tested for
- Cerebral Amyloid Angiopathy, Down Syndrome-Associated Alzheimer's Disease (DS-AD), Early-Onset Alzheimer Disease
- Main trialPhase 2
- “The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 50 months.”In the company’s words, NCT06393712 on ClinicalTrials.gov
- Other names
- ALN-APP
Other drugs for Cerebral Amyloid Angiopathy
- AMDX-2011PAmydis Inc. · Phase 2
Coming up3
- 9 Aug 2027Phase 2 trial completes · ClinicalTrials.gov
- 11 Jan 2029Phase 1 trial completes · ClinicalTrials.gov
- 18 May 2030Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 9 Aug 2027 | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy | |
| Phase 2Recruiting | 18 May 2030 | A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD) | |
| Phase 1Recruiting | 11 Jan 2029 | A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026